Copenhagen, Denmark; December 6, 2013 – Genmab A/S (OMX: GEN) announced today it had reached an in vivo pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1.5 million payment (approximately DKK 11 million). Under the collaboration with Lundbeck, Genmab creates novel human antibodies to three central nervous system (CNS) targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities.
Help employers find you! Check out all the jobs and post your resume.
